Patent · US Expired

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

US7923534B1 · kind B1 · utility

0Cited by

5References

3Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Thierry Boon · Brussels, BE
Pierre van der Bruggen · Brussels, BE
Benoit Van den Eynde · Brussels, BE
Aline Van Pel · Brussels, BE
Etienne De Plaen · Brussels, BE
Christophe Lurquin · Brussels, BE
Patrick Chomez · Brussels, BE
Catia Traversari · Milano, IT

Key dates

Filing date	Mar 17, 1997
Grant date	Apr 12, 2011
Priority date	—
Expiry date	Mar 17, 2017

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/828
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.